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Allogeneic haemopoietic stem cell transplant (Allo-HSCT) is used 
to treat a broad but well-defined range of paediatric conditions, 
most frequently in paediatric oncology for treatment intensification 
or salvage therapy for acute myeloid leukaemia (AML) and acute 
lymphoblastic leukaemia (ALL). Allo-HSCT is also indicated in 
juvenile myelomonocytic leukaemia (JMML) should a suitable donor 
be available.[1] There is still a role for sibling matched Allo-HSCT 
in chronic myeloid leukaemia (CML), despite the good long-term 
survival demonstrated with the use of tyrosine kinase inhibitors. [2] 
Allo-HSCT is also used as salvage therapy in the treatment of 
paediatric lymphoma.[3] In 2007, ~150 new cases of leukaemia per 
annum in children aged <14 years were being captured on the South 
African Children’s Cancer Group registry.[4] Only a small number 
of these children with high-risk disease require Allo-HSCT.[5,6] The 
current demography of donors on the South African Bone Marrow 
Registry (SABMR) does not represent the wide ethnic diversity 
of patients in our country. Owing to poor representation of local 
genotypes on local and international registries, a proportion of 
patients who qualify for treatment with Allo-HSCT cannot access a 
transplant because no suitable donors are available.[7]
Allo-HSCT is an effective strategy for a number of non-oncological 
haematological conditions such as bone marrow failure syndromes. 
These include severe acquired aplastic anaemia (SIAA) and Fanconi’s 
anaemia (FA).[8] Haemoglobinopathies such as homozygous beta-
thalassaemia and sickle cell disease (SCD) are cured with successful 
Allo-HSCT.[9] At Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, South Africa, approximately four new 
patients are diagnosed annually with bone marrow failure syndromes. 
The number of patients with SCD who attend the haematology clinic 
has expanded to nearly 150. Currently 8 transfusion-dependent 
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Background. Allogeneic haemopoietic stem cell transplant (Allo-HSCT) is a specialised and costly intervention, associated with significant 
morbidity and mortality. It is used to treat a broad range of paediatric conditions. South Africa (SA) is an upper middle-income country 
with limitations on healthcare spending. The role of paediatric Allo-HSCT in this setting is reviewed.
Objectives. To review paediatric patients who underwent Allo-HSCT at the Groote Schuur Hospital/University of Cape Town Private 
Academic Hospital transplant unit in Cape Town, South Africa, and received post-transplant care at Red Cross War Memorial Children’s 
Hospital, over the period January 2006 - December 2014 in respect of indications for the transplant, donor sources, conditioning regimens, 
treatment-related morbidity and overall survival (OS).
Methods. A retrospective analysis of patient records was performed and a database was created in Microsoft Access. Descriptive analyses 
of relevant demographic, clinical and laboratory data were performed. Summary statistics of demographic and clinical parameters were 
derived with Excel. OS was calculated from the date of transplant to the date of an event (death) or last follow-up using the Kaplan-Meier 
method in Statistica.
Results. A total of 48 children received Allo-HSCT: 24 for haematological malignancies, 20 for non-oncological haematological conditions, 
3 for immune disorders and 1 for adrenoleukodystrophy. There were 28 boys (median age 7.5 years) and 20 girls (8.5 years). There were 
31 sibling matched peripheral-blood stem cell (PBSC) transplants and 1 maternal haploidentical PBSC transplant. Stem cells were mobilised 
from bone marrow into peripheral blood by administering granulocyte-colony stimulating factor to donors. PBSCs were harvested by 
apheresis. Eight patients received 10/10 HLA-matched grafts from unrelated donors. Six were PBSC grafts and 2 were bone marrow grafts. 
Three of the unrelated PBSC grafts were from SA donors. Eight transplants used umbilical cord blood from international registries. OS for 
patients with non-oncological disorders was 91.3% (median follow-up 3.9 years), while that for oncology patients was 56.8% (1.9 years). 
Two of the survivors developed chronic graft-versus-host disease.
Conclusions. OS for non-oncological conditions was excellent, while outcomes for oncological disorders were on par with those in high-
income settings. Transplantation offers many patients the opportunity for long-term survival and has been shown to be both feasible and 
rewarding in a less well-resourced environment servicing an economically diverse population.
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thalassaemia patients attend RCWMCH: 5 with homozygous beta-
thalassaemia and 3 with severe haemoglobin E/beta-thalassaemia.
Primary immunodeficiency disorders (PIDs) can be ameliorated 
by Allo-HSCT.[10] A recent publication[11] highlighting new diagnostic 
and treatment modalities aimed to increase awareness, detection and 
diagnosis of PIDs among SA paediatricians. Allo-HSCT can also be 
used to treat rarer metabolic conditions such as the liposomal storage 
diseases and infantile osteopetrosis as well as adrenoleukodystrophy, 
in which it has been shown to arrest or slow neurodegeneration.[12]
Allo-HSCT is a highly specialised and costly intervention, 
associated with significant morbidity and mortality. As scientific 
knowledge improves, so does HLA typing and matching.[13] Combined 
with better supportive care, this has led to improved survival rates of 
Allo-HSCT patients.[14]
The role of Allo-HSCT in the context of a resource-limited upper 
middle-income country[15] must be reviewed and critically analysed to 
ensure that this intervention is being used safely and cost-effectively.
Children receiving healthcare in SA fall into two categories. 
According to the SA National Fiscal Review in 2011,[16] the vast 
majority (84%) receive state-funded healthcare. A smaller group have 
medical insurance. The policy at RCWMCH allows for state-funded 
patients to be eligible for a sibling matched transplant or a 10/10 HLA-
matched transplant from an unrelated SA donor. The tissue typing 
and donor recruitment are funded by a non-profit organisation, the 
Sunflower Fund. For patients with medical insurance, an international 
donor search can be accessed. In recent figures quoted by the 
SABMR, this expense may range from ZAR300 000 to ZAR700 000, 
depending on where the graft is sourced and the exchange rate. Not 
all medical insurance policies will cover this expense.
Objectives
Paediatric patients who underwent Allo-HSCT at the Groote Schuur 
Hospital (GSH)/University of Cape Town (UCT) Private Academic 
Hospital Transplant Unit in Cape Town and received post-transplant 
care at RCWMCH from January 2006 to December 2014 were 
reviewed in respect of the indications for the transplant, donor 
sources, conditioning regimens, treatment-related morbidity and 
overall survival (OS). The results of these findings were used to assess 
the feasibility of Allo-HSCT as well as justify the huge demand on 
resources required to sustain an Allo-HSCT programme providing 
potential cure to a small group of patients with otherwise life-
threatening illnesses in the SA setting.
Methods
The folders of all paediatric patients, including those diagnosed and 
referred from other centres, who received treatment with Allo-HSCT 
or a bone marrow transplant at the GSH/UCT Private Academic 
Hospital Transplant Unit and post-transplant care at RCWMCH 
from January 2006 to December 2014 were retrospectively reviewed 
in December 2015. Follow-up was limited to the end of November 
2015. A database was created in Microsoft Access 2007 (USA), 
and descriptive analyses of relevant demographic, clinical and 
laboratory data were performed. Specific data collected included 
sex of the patient, age at transplant, indication for transplant, 
treatment prior to transplant, conditioning regimens, haemopoietic 
stem cell (HSC) source, immunosuppression and graft-versus-host 
disease (GvHD) prophylaxis, documented infections (i.e. clinically 
significant positive blood culture, urine culture, nasopharyngeal 
aspirate and pus swab results), GvHD site, date of discharge 
from the transplant unit, cytomegalovirus (CMV) reactivation, 
transplant outcome and cause of death. The families of patients who 
were alive and did not have entries within the month of November 
2015 in their folders were contacted telephonically to ascertain the 
child’s health status.
Summary statistics of demographic, clinical and relevant labora-
tory parameters were derived with Excel 2007 (Microsoft, USA). OS 
was calculated from the date of transplant to the date of an event 
(death) or the last follow-up using the Kaplan-Meier method on 
Statistica 13.2 (StatSoft, USA).
Ethical approval was obtained from the UCT Human Research 
Ethics Committee (ref. no. 082/2015) and Netcare Operations 
Committee (ref. no. MED-2015-001).
During the transplant, infection prophylaxis included 
oral valacyclovir (20 mg/kg/dose 8-hourly) for CMV and oral 
co-trimoxazole (20/100 mg for patients aged <6 months, 40/200 mg 
for those aged 6 months - 6 years and 80/400 mg for those aged 
>6  years) for Pneumocystis jiroveci pneumonia (PJP). There is 
evidence to support the use of valacyclovir over acyclovir in the 
prevention of CMV reactivation.[17] Patients also received fluconazole 
(5 mg/kg/d orally or intravenously) as fungal prophylaxis, as well as 
prophylactic oral ofloxacin (5 mg/kg 12-hourly). Primary care was 
provided by the transplant physicians at GSH with support from 
paediatric services at RCWMCH. Children remained in the unit 
until they achieved neutrophil engraftment, at which time they 
were either discharged home or transferred to RCWMCH. At GSH 
patients were treated in reverse isolation. Each room has laminar 
flow and high-efficiency particulate arrestance (HEPA) filtration, 
and a separate shower and toilet. Five patients were transferred to 
RCWMCH prior to engraftment because they required paediatric 
intensive care unit (PICU) support. During this period there were 
no isolation facilities or rooms with laminar flow or HEPA filtration 
in the RCWMCH PICU. There was a single isolation cubicle with 
laminar flow but no HEPA filtration in the oncology unit for bone 
marrow transplant patients.
Patients continued to receive supportive care at RCWMCH 
until at least 12 weeks after the transplant, with weekly 10 mL/
kg infusions of stabilised human serum (SHS), surveillance for 
GvHD, monitoring of cyclosporine levels and CMV reactivation 
surveillance with polymerase chain reaction and routine blood 
tests including full blood count, liver function tests, measurement 
of electrolyte levels and tests for renal function. It is common 
practice to use intravenous immunoglobulin G (IVIG) for CMV 
prophylaxis after Allo-HSCT to decrease infections and CMV 
reactivation.[18] SHS supplied by the Western Province Blood 
Transfusion Service is rich in immunoglobulin G (10 g/L).[19] 
Although CMV prophylaxis is not one of the indications for its use, 
SHS was used in these patients for this purpose instead of IVIG as 
it was more cost-effective. Ongoing blood product support was also 
administered, if required, at ongoing follow-up visits at RCWMCH 
once patients had been discharged from hospital. Children who 
developed CMV reactivation were admitted to RCWMCH for 
administration of intravenous ganciclovir. Similarly, those who 
developed intercurrent infections were admitted for broad-
spectrum intravenous antibiotics. Patients who developed GvHD 
were admitted for further investigation such as colonoscopy and 
biopsy or skin biopsy, and management with corticosteroids and 
other immunosupression. CMV and PJP prophylaxis was continued 
until immunosuppression had been successfully withdrawn.
Once immunosupression was withdrawn, patients either remained 
at RCWMCH or returned to their referring centres, where follow-up 
continued. They were commenced on a reimmunisation schedule 
1 year after the transplant.
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Results
During the 9-year study period, 48 children received an Allo-HSCT. 
Eighteen (37.5%) were state-funded transplants. Twenty-eight boys 
(median age 7.5 years) and 20 girls (median age 8.5 years), with an 
overall age range of 9 months - 12.3 years, had transplants. Of the 
48 patients, 38 (79.2%) received peripheral-blood stem cell (PBSC) 
transplants: 31 of the PBSC grafts were 10/10 HLA-matched grafts 
from a sibling, 6 were HLA-matched grafts from an unrelated donor, 
and 1 was a maternal haploidentical graft.
Stem cells were mobilised using twice-daily subcutaneous injec-
tions of granulocyte-colony stimulating factor 5 µg/kg 12-hourly 
and harvested by apheresis on day 5 through a femoral dialysis 
line. Twenty of these PBSC transplants were T-cell depleted using 
ex vivo addition of alemtuzumab (1 mg/108 mononuclear cells) to 
the graft. [20]
Two patients received bone marrow grafts from unrelated donors. 
All unrelated bone marrow grafts were 10/10 HLA-matched donor-
recipient pairs. Eight patients received umbilical cord blood (UCB) 
transplants from international registries. Three of the unrelated HLA-
matched grafts were from SA donors. Procurement of all unrelated 
grafts was facilitated by the SABMR.
There were 24 patients who received an Allo-HSCT for an 
underlying malignancy. These transplants are described in Table 1.
Of the 10 patients who received transplants for ALL, 9 had 
relapsed disease and were in a second or subsequent remission. 
One patient was transplanted in first remission for a balanced 
translocation (1; 19). Five of the ALL patients died after the trans-
plant. One patient died of relapsed disease, 7 months after a non-
T-cell-depleted PBSC transplant, 1 died of pneumonia 1 month 
after a 4/6 HLA-matched unrelated UCB transplant, and 3 died of 
complications of GvHD after the transplant. These patients were 
a child who died 2 months after a 6/6 HLA-matched unrelated 
UCB transplant following a complicated course including BK virus 
infection, cyclosporine toxicity, renal failure, central pontine myelin-
olysis and adenovirus pneumonia, a child who died 4 months after a 
4/6 HLA-matched unrelated UCB transplant following an ascending 
BK virus infection involving the kidney, and a child who died from 
chronic lung disease 5 months after a non-T-cell-depleted sibling 
matched PBSC transplant.
Nine patients with AML received transplants. Only 2 of these 
had relapsed disease. They were both in remission following 
reinduction chemotherapy before the transplant, and both died 
after the transplant. One patient relapsed, while the other developed 
chronic GvHD and died from sepsis. The other 7 AML patients were 
transplanted in first remission because of assignment of high risk 
based on cytogenetics, or poor response to induction chemotherapy. 
Four children were referred for transplantation because they were not 
in remission at the end of the induction. Two of these children died 
from relapsed disease after the transplant. At RCWMCH all patients 
with AML, except those with good-risk cytogenetics, are considered 
for sibling HLA-matched Allo-HSCT in first remission. There was 
one such patient in this cohort of nine. Good-risk cytogenetics 
include translocation (8; 21), inversion 16 and translocation (16; 16). 
Standard-risk patients include all those with neither good- nor 
poor-risk cytogenetics and those who are in remission after the first 
induction block. There was one patient who met these criteria. Poor-
risk cytogenetics include monosomy 5 or 7, deletion (5q), abnormal 
(3q), translocation (9; 22) and more than five major karyotype 
abnormalities. Two patients with monosomy 7 were transplanted.
The two patients transplanted for JMML were both alive and well 
at the time of writing, the patient who received a 5/6 HLA-matched 
unrelated UCB transplant at 6 years after the transplant and the 
patient who received the matched unrelated PBSC transplant at 
4 years and 7 months after the transplant.
There were 24 patients who received transplants for non-
oncological indications (Table 2), of whom 14 were alive and 
in remission at the time of writing, with a median follow-up of 
1.86  years (range 36  days - 7.3 years). OS was 56.8%. Transplant-
related mortality (TRM) at 100 days post transplant was 12.5%. Fig. 1 
demonstrates the overall survival curve for these transplants.
Six children had transfusion-dependent disorders: 4 had thalass-
aemia major, 1 sideroblastic anaemia (SA) and 1 haemolytic anaemia 
(HA). HA is an unusual indication for Allo-HSCT, and the decision 
to recommend Allo-HSCT in this patient was made after exhaustive 
testing failed to identify the cause of the child’s ongoing haemolysis, 
which required ongoing regular transfusion. Two patients had SCD, 
one of whom had sickle-haemoglobin D-Punjab. Both patients had 
recurrent painful crises, and matched sibling donors were available. 
They received non-T-cell-depleted PBSC grafts.
Eleven patients had bone marrow failure syndromes. Of these, 
4 had SIAA: 3 of these patients received T-cell-depleted sibling 
matched PBSC grafts and 1 a 10/10 HLA-matched unrelated 
PBSC graft from an international donor. Seven patients had FA. 
Of these, 5 received sibling matched PBSC grafts, 3 of which were 
T-cell depleted, 1 received a T-cell-depleted sibling matched bone 
marrow graft, and 1 received a T-cell-depleted matched unrelated 
PBSC graft. One patient with myelodysplasia (MD) received a 
non-T-cell-depleted matched unrelated PBSC graft. There was 
only 1 death among these 11 patients. This was a patient with FA 
transplanted with a non-T-cell-depleted sibling matched PBSC graft 
who developed GvHD and then died of graft failure 5 months after 
the transplant.
Three children were transplanted for immunodeficiency. These 
included 2 patients with severe combined immunodeficiency dis-
order (SCID), of whom 1 received a 5/6 HLA-matched UCB graft 
and 1 a T-cell-depleted maternal haploidentical PBSC graft. The third 
patient had immunodysregulation polyendocrinopathy enteropathy 
X-linked (IPEX) syndrome. This patient received a 10/10 HLA-
matched unrelated graft. All 3 patients were alive at the time of 
writing.
One child with adrenoleukodystrophy received a non-T-cell-
depleted sibling matched PBSC graft. He was doing well at the time 
of writing, and his neuroregression had been arrested.
Of the 24 patients transplanted for non-oncological conditions, 22 
were alive at the time of writing, at a median follow-up of 3.94 years 
(range 87 days - 9.22 years). OS was 91.3%, and TRM at 100 days post 
transplant was 0%. The overall survival curve for these transplants is 
shown in Fig. 2.
Three patients have experienced chronic GvHD. Two of these 
patients were still receiving immunosuppression at the time of 
writing. Both had received T-cell-depleted sibling matched PBSC 
transplants, the first patient for relapsed ALL and the other for SIAA. 
The patient with ALL was receiving low-dose prednisone for chronic 
immune-mediated fasciitis 17 months post transplant. The patient 
with SIAA, who was being treated with mycophenolic acid and 
prednisone for eosinophilic myositis and fasciitis, was 4  years and 
8 months post transplant at the time of writing. The third patient, 
who was transplanted for SCD, had chronic GvHD involving the 
skin, gut and liver and eosinophilic myositis and fasciitis with a 
complex regional pain syndrome requiring long-term treatment 
with corticosteroids and tacrolimus for 2 years post transplant. This 
patient was doing well after 1 year off all immunosuppression.
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Table 1. Transplants for oncological indications
Case 
no. Graft
T-cell 
depleted Diagnosis
Indication for 
transplant Conditioning regimens
GvHD 
prophylaxis
CMV 
reactivation Outcome
1 UCB 6/6 No ALL Relapsed disease TBI/fludarabine Cyclosporine No Died 4 mo post transplant 
from acute GvHD/adeno-
virus/renal failure
2 UCB 5/6 No JMML Failed ATRA 
treatment
Busulphan/fludarabine/
melphalan
Cyclosporine No Alive and well
3 UCB 5/6 No Hepatosplenic 
gamma/delta 
lymphoma
Hepatosplenic 
gamma/delta 
lymphoma
Busulphan/fludarabine/
melphalan
Cyclosporine No Alive and well
4 UCB 5/6 Yes ALL Relapsed disease TBI/fludarabine Cyclosporine No Alive and well
5 UCB 4/6 No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide/ATG
Cyclosporine No Died 1 mo post transplant 
from pneumonia
6 UCB 4/6 No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide/ATG
Cyclosporine No Died 4 mo post transplant 
from acute GvHD
7 UCB 4/6 No AML AML monosomy 
7
Busulphan/melphalan/
cyclophosphamide
Cyclosporine No Died 3.5 mo post 
transplant from acute gut 
GvHD
8 Sibling matched 
PBSC
No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide/ATG
Cyclosporine No Died 7 mo post transplant 
from relapsed ALL
9 Sibling matched 
PBSC
No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide
Cyclosporine No Died 5 mo post transplant 
from chronic lung GvHD
10 Sibling matched 
PBSC
No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide
Cyclosporine/
methotrexate
No Alive and well
11 Sibling matched 
PBSC
No ALL Relapsed disease TBI/fludarabine/
cyclophosphamide
Cyclosporine No Alive and well
12 Sibling matched 
PBSC
Yes ALL Relapsed disease TBI/fludarabine Cyclosporine No Alive
Chronic GvHD
13 Sibling matched 
PBSC
Yes ALL Translocation 
(1; 19)
TBI/fludarabine Cyclosporine Yes Alive and well
14 Sibling matched 
PBSC
Yes AML Failure to remit 
after induction 1
Busulphan/melphalan/
cyclophosphamide
Cyclosporine Yes Alive and well
15 Sibling matched 
PBSC
Yes AML Relapsed disease Busulphan/melphalan/
cyclophosphamide
Cyclosporine No Died 26 mo post 
transplant of relapsed 
disease
16 Sibling matched 
PBSC
Yes AML Failure to remit 
after induction 1
Reduced intensity: 
busulphan/melphalan/
fludarabine
Cyclosporine No Died 8 mo post transplant 
of relapsed disease
17 Sibling matched 
PBSC
No AML Failure to remit 
after induction 1
Busulphan/melphalan/
cyclophosphamide
Cyclosporine Yes Died 5 mo post transplant 
of relapsed disease
18 Sibling matched 
PBSC
No AML Relapsed disease Busulphan/melphalan/
cyclophosphamide
Cyclosporine/
methotrexate
Yes Died 6 mo post transplant 
of chronic GvHD/sepsis
19 Sibling matched 
PBSC
Yes AML Standard risk 
with sibling 
donor available
Busulphan/melphalan/
cyclophosphamide/ATG
Cyclosporine No Alive and well
20 Sibling matched 
PBSC
Yes AML Failure to remit 
after induction 1
Busulphan/melphalan/
cyclophosphamide
Cyclosporine Yes Alive and well
21 Sibling matched 
PBSC
No CML Relapsed on 
imatinib
Busulphan/melphalan/
cyclophosphamide
Cyclosporine No Alive and well
22 Matched 
unrelated PBSC
Yes AML AML monosomy 
7
Busulphan/melphalan/
cyclophosphamide/ATG
Cyclosporine Yes Alive and well
23 Matched 
unrelated PBSC
No JMML Failed CRA 
treatment
Busulphan/melphalan/
cyclophosphamide/ATG
Cyclosporine No Alive and well
24 Matched 
unrelated PBSC
Yes ALCL Relapsed disease Busulphan/melphalan/
cyclophosphamide/ATG
Cyclosporine No Alive and well
TBI = total body irradiation; ATRA = all-trans retinoic acid; ATG = antithymocyte globulin; CRA = cis-retinoic acid. 
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Discussion
The Cape Town paediatric transplant experience has been a major 
success, demonstrating OS of 91.3% with median follow-up of 
3.94 years for non-oncological indications. TRM at 100 days post 
transplant for non-oncological indications was 0%. The OS for 
haematopoietic malignancies was 56.8% with a median follow-up 
of 1.86 years and TRM at 100 days post transplant of 12.5%. It is 
not possible to compare the outcomes of Allo-HSCT performed 
for oncological and non-oncological conditions. Our outcomes 
(OS  44.4%) for children treated for relapsed ALL are in keeping 
with experience in the developed world,[5,21] and Allo-HSCT offered 
the best potential cure to these children. The results for patients with 
Table 2. Transplants for non-oncological indications
Case 
no. Graft
T-cell 
depleted Diagnosis Conditioning GvHD prophylaxis
CMV 
reactivation Outcome
1 Sibling matched PBSC No FA Busulphan/fludarabine/
cyclophosphamide/ATG/
alemtuzumab
Cyclosporine Yes Died 5 mo post 
transplant  
Developed GvHD 
and then graft failure
2 Sibling matched PBSC No FA Busulphan/fludarabine/ATG Cyclosporine No Alive and well
3 Sibling matched PBSC No FA Fludarabine/cyclophosphamide/
ATG
Cyclosporine/
methotrexate
No Alive and well
4 Sibling matched PBSC Yes FA Busulphan/fludarabine/
cyclophosphamide/ATG
Cyclosporine Yes Alive and well
5 Sibling matched PBSC Yes FA Busulphan/fludarabine/ATG Cyclosporine No Alive
Chronic GvHD
6 Sibling matched PBSC Yes SIAA Busulphan/fludarabine/
cyclophosphamide/ATG
Cyclosporine No Alive and well
7 Sibling matched PBSC Yes SIAA Fludarabine/cyclophosphamide Cyclosporine No Alive and well
8 Sibling matched PBSC Yes SIAA Fludarabine/cyclophosphamide Cyclosporine No Died 6 mo post 
transplant from 
Gram-negative 
septicaemia
9 Sibling matched PBSC Yes Thalassaemia major Busulphan/fludarabine/ATG Cyclosporine No Alive and well
10 Sibling matched PBSC Yes Thalassaemia major Busulphan/fludarabine/ATG Cyclosporine No Alive and well
11 Sibling matched PBSC No Thalassaemia major Busulphan/fludarabine/ATG Cyclosporine No Alive and well
12 Sibling matched PBSC No Thalassaemia major Busulphan/fludarabine/ATG Cyclosporine No Alive and well
13 Sibling matched PBSC No Sickle-haemoglobin 
D-Punjab
Busulphan/fludarabine/
cyclophosphamide/ATG
Cyclosporine/
methotrexate
No Alive and well
14 Sibling matched PBSC No SCD Busulphan/fludarabine/
cyclophosphamide/ATG
Cyclosporine No Alive and well
15 Sibling matched PBSC Yes SA Busulphan/fludarabine/ATG Cyclosporine No Alive and well
16 Sibling matched PBSC No HA Busulphan/fludarabine/cyclo-
phosphamide/melphalan/ATG
Cyclosporine No Alive and well
17 Sibling matched PBSC Yes Adrenoleukodystrophy Busulphan/fludarabine/ATG Cyclosporine No Alive and well
18 Sibling matched bone 
marrow
Yes FA Fludarabine/cyclophosphamide/
ATG
Cyclosporine No Alive and well
19 Matched unrelated 
PBSC
Yes FA Fludarabine/cyclophosphamide Cyclosporine Yes Alive and well
20 Matched unrelated 
PBSC
No SIAA Busulphan/fludarabine/
cyclophosphamide/ATG
Cyclosporine/
methotrexate
No Alive and well
21 Matched unrelated 
PBSC
No MD Busulphan/melphalan/
cyclophosphamide/ATG
Cyclosporine Yes Alive and well
22 Matched unrelated 
bone marrow
No IPEX Busulphan/fludarabine/ATG Mycophenolate 
mofetil/tacrolimus
No Alive and well
23 Haploidentical PBSC Yes SCID Busulphan/fludarabine/
alemtuzumab
Cyclosporine No Alive and well
24 UCB 5/6 No SCID Busulphan/fludarabine/ATG Cyclosporine/
methotrexate
No Alive and well
ATG = antithymocyte globulin.
237       March 2017, Vol. 107, No. 3
RESEARCH
AML (OS 44.4%) are also comparable to those from units in high-
income settings.[22]
Only three of the 36 surviving patients (8.3%) have experienced 
chronic GvHD requiring ongoing immunosuppression, suggesting 
that ex vivo T-cell depletion of the PBSC grafts has been effective in 
reducing the incidence of GvHD. Some of the literature on paediatric 
Allo-HSCT favours the use of bone marrow as a source of graft over 
PBSCs owing to the increased risk of chronic GvHD with PBSCs. [23] 
Most of the transplants at GSH and the UCT Private Academic 
Hospital made use of PBSC grafts. The use of T-cell depletion by 
exposure of the PBSC graft to alemtuzumab ex vivo to prevent GvHD 
was described by Hale and Waldmann[24] in 1993. Wood et al.[25] from 
Cape Town reported gratifying results with regard to quality of life 
and a low incidence of GvHD when using this technique in an adult 
population in 1994. Our experience has corroborated these findings.
Although T-cell depletion may carry the potential risk of increased 
viral complications after the transplant,[26] we have found ex vivo 
immunodepletion of grafts to be effective and safe, with only 9 of 
48 transplants (18.8%) being complicated by CMV reactivation. 
There were no deaths due to CMV reactivation, but one patient was 
re-transplanted after overwhelming CMV infection resulted in graft 
failure. The patient did very well after the second graft. This is in 
keeping with the morbidity described in an adult cohort from GSH[27] 
and is also below the 30% suggested by Azevedo et al.[28]
Successful Allo-HSCT can significantly improve quality of life for 
patients requiring regular transfusion.[9] It reduces the cumulative 
financial burden of blood products, chelation and treatment of 
iron overload-related morbidity, which place an enormous load on 
an already overburdened healthcare system. Current monthly cost 
estimates for a child include admission to hospital (ZAR1 900/day), 
filtered packed red cells (ZAR1 500/unit) and chelation (deferasirox 
ZAR2 300 - 5 000/month). Our considerable success in this group of 
patients, although a small cohort (n=4), suggests that Allo-HSCT is a 
very favourable therapeutic intervention in these cases.
Allo-HSCT is the only curative option for children affected by 
SCD, offering longevity and improved quality of life if performed 
timeously and for the correct indications. Current guidelines for 
paediatric patients are that it should be reserved for children aged 
<17 years, those with severe symptoms of SCD, unresponsive 
to hydroxyurea, and those with SCD-related organ damage (e.g. 
stroke, acute chest syndrome, multiple sites of osteonecrosis), if a 
sibling matched donor is available.[9] As migration brings a growing 
number of these patients into SA,[29] transplantation may need to be 
considered to an increasing extent.
Conclusions
In this cohort, the source of HSCs and access to Allo-HSCT 
were largely determined by the patients’ economic resources and 
availability of suitable donors on the SABMR. OS for non-oncological 
conditions was excellent, while outcomes for oncological disorders 
were on par with those in high-income settings. Transplantation 
presented the best opportunity for long-term survival for the children 
who underwent the procedure.
Allo-HSCT has an important role to play in the management of 
paediatric patients. Despite local resource challenges, innovative and 
judicious use of this modality in respect of indication and recipient 
choice, as well as HSC source, will ensure successful outcomes and 
sustainability of this instrument. Patients who are eligible for Allo-
HSCT and their siblings should therefore be tissue typed. Increasing 
donor awareness is critical in SA. Higher numbers of available local 
donors increase patients’ chance of a suitable HLA match.
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Fig. 1. Overall survival curve for oncological indications.
Fig. 2. Overall survival curve for non-oncological indications.
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